Status:
COMPLETED
Inflammatory Cytokines in Symptom Production in Multiple Myeloma
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
AstraZeneca
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this research study is to learn about the pain and/or other symptoms that patients may experience either while you are being monitored by your doctor before a decision is made to start you...
Detailed Description
If you agree to take part in this study, you will complete 5 questionnaires during a regularly scheduled clinic visit. These questionnaires will measure pain and other symptoms, such as your mood and ...
Eligibility Criteria
Inclusion
- Must speak and understand English;
- Must be diagnosed with MM and meet one of the following criteria: 1) have been treated for MM with steroids only, or have received no more than two cycles of induction chemotherapy for MM and are going to be treated with bortezomib or thalidomide for induction therapy; 2) have received induction therapy and have been approved (or are being approved) medically and financially to receive autologous hematopoietic stem cell transplantation (Auto-HSCT); 3) cross sectional study patients will be either with a current diagnosis of asymptomatic MM not receiving treatment; or at least 12 months from the MM diagnosis, had received induction therapy, with or without received autologous hematopoietic stem cell transplantation (Auto-HSCT) and follow-up treatments. This cohort for a cross sectional survey may include the cases been enrolled, either completed or dropped from the same study. It may also include patients who did not participate on the first phase of the protocol (longitudinal cohort).
- Patients \>= 18 years old.
Exclusion
- Patients who do not understand the intent of the study, so cannot or will not give informed consent
- Patients who are unable to use the Interactive Voice Response (IVR) system due to physical limitations (e.g., hearing impairment).
- Induction therapy patients with a neuropathy score of 3 or greater on the NCI's Common Terminology Criteria (CTC version 3.0) either at the beginning of induction chemotherapy or after 1-2 cycles of chemotherapy as a result of previous treatment or from some other comorbid cause. This exclusion criteria does apply to the auto-HSCT patients.
Key Trial Info
Start Date :
May 9 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 8 2019
Estimated Enrollment :
491 Patients enrolled
Trial Details
Trial ID
NCT00688168
Start Date
May 9 2008
End Date
January 8 2019
Last Update
May 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030